| The human histone deacetylase family SG Gray, TJ Ekström Experimental cell research 262 (2), 75-83, 2001 | 776 | 2001 |
| circular RNAs: biogenesis, function and role in human diseases J Greene, AM Baird, L Brady, M Lim, SG Gray, R McDermott, SP Finn Frontiers in Molecular Biosciences 4, 2017 | 512 | 2017 |
| Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis S Camelo, AH Iglesias, D Hwang, B Due, H Ryu, K Smith, SG Gray, ... Journal of neuroimmunology 164 (1), 10-21, 2005 | 329 | 2005 |
| Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature MP Barr, SG Gray, AC Hoffmann, RA Hilger, J Thomale, JD O’Flaherty, ... PloS one 8 (1), e54193, 2013 | 314 | 2013 |
| Molecular subclassification of kidney tumors and the discovery of new diagnostic markers M Takahashi, XJ Yang, J Sugimura, J Backdahl, M Tretiakova, CN Qian, ... Oncogene 22 (43), 6810-6818, 2003 | 242 | 2003 |
| Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer JD O’Flaherty, S Gray, D Richard, D Fennell, JJ O’Leary, FH Blackhall, ... Lung Cancer 76 (1), 19-25, 2012 | 211 | 2012 |
| NF‐κB regulation: the nuclear response AK Mankan, MW Lawless, SG Gray, D Kelleher, R McManus Journal of cellular and molecular medicine 13 (4), 631-643, 2009 | 202 | 2009 |
| Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells R Heery, SP Finn, S Cuffe, SG Gray Cancers 9 (4), 38, 2017 | 182 | 2017 |
| Role of histone and transcription factor acetylation in diabetes pathogenesis SG Gray, P De Meyts Diabetes/metabolism research and reviews 21 (5), 416-433, 2005 | 162 | 2005 |
| Functional characterization of JMJD2A, a histone deacetylase-and retinoblastoma-binding protein SG Gray, AH Iglesias, F Lizcano, R Villanueva, S Camelo, H Jingu, ... Journal of Biological Chemistry 280 (31), 28507-28518, 2005 | 161 | 2005 |
| Lung cancer stem cells: The root of resistance L MacDonagh, SG Gray, E Breen, S Cuffe, SP Finn, KJ O'Byrne, MP Barr Cancer Letters, 2016 | 158 | 2016 |
| Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p16 1 M Kjellman, L Roshani, BT Teh, OP Kallioniemi, A Höög, S Gray, ... The Journal of Clinical Endocrinology & Metabolism 84 (2), 730-735, 1999 | 133 | 1999 |
| Histone acetylation/deacetylation and cancer: an “open” and “shut” case? SG Gray, BT Teh Current molecular medicine 1 (4), 401-429, 2001 | 126 | 2001 |
| Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis SG Gray, F Dangond Epigenetics 1 (2), 67-75, 2006 | 124 | 2006 |
| The RNA Methyltransferase NSUN2 and Its Potential Roles in Cancer A Chellamuthu, SG Gray Cells 9 (8), 1758, 2020 | 119 | 2020 |
| Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy MW Lawless, KJ O’Byrne, SG Gray Journal of cellular and molecular medicine 13 (9a), 2800-2821, 2009 | 118 | 2009 |
| The emerging role of microRNAs in resistance to lung cancer treatments L MacDonagh, SG Gray, SP Finn, S Cuffe, KJ O’Byrne, MP Barr Cancer treatment reviews 41 (2), 160-169, 2015 | 110 | 2015 |
| Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines SG Gray, CN Qian, K Furge, X Guo, BT Teh International journal of oncology 24 (4), 773-795, 2004 | 110 | 2004 |
| Receptor tyrosine kinases and their activation in melanoma DJ Easty, SG Gray, KJ O’Byrne, D O’Donnell, DC Bennett Pigment cell & melanoma research 24 (3), 446-461, 2011 | 103 | 2011 |
| BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC L MacDonagh, SG Gray, E Breen, S Cuffe, SP Finn, KJ O'Byrne, MP Barr Cancer letters 428, 117-126, 2018 | 78 | 2018 |
kenneth o'byrneQueensland University of Technology; Princess Alexandra Hospital; Translational Research Institute在 qut.edu.au 的电子邮件经过验证
